Metsera, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MTSR research report →
Range $54 – $57
Price Chart
About the company
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues.
- CEO
- Christopher Whitten Bernard
- IPO
- 2025
- Employees
- 93
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on MTSR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.43B
- P/E
- -28.09
- PEG
- -11.73
- P/S
- 0.00
- P/B
- 21.96
- EV/EBITDA
- -26.72
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -60.74%
- ROIC
- -59.10%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-224,833,000
- Net Income
- $-209,127,000-343.0%
- EPS
- $-2.03-113.7%
- OCF Growth
- -181.9%
- FCF Growth
- -181.8%
- 52W High
- $83.86
- 52W Low
- $12.30
- 50D MA
- $53.47
- 200D MA
- $35.09
- Beta
- 1.70
- RSI (14)
- 62
- Avg Volume
- 3.50M
No earnings-call transcripts are available for MTSR yet.
- Free Float
- 45.7%
- Shares Outstanding
- 105.38M
- Float Shares
- 48.15M
of shares held by institutions
112 13F filers
Buy/sell ratio 0.37. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 25 | FMR LLC | other | 2,230,450 |
| Nov 13, 25 | ARCH Venture Partners XII, LLC | sell | 8,313,680 |
| Nov 13, 25 | Marso Steven | other | 17,000 |
| Nov 13, 25 | Marso Steven | sell | 17,000 |
| Nov 13, 25 | Marso Steven | sell | 21,279 |
| Nov 13, 25 | Marso Steven | sell | 120,000 |
| Nov 13, 25 | BERNS PAUL L | other | 4,031 |
| Nov 13, 25 | BERNS PAUL L | sell | 24,188 |
| Nov 13, 25 | BERNS PAUL L | sell | 223,430 |
| Nov 13, 25 | BERNS PAUL L | sell | 957,559 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MTSR coverage
Recent articles, reports, and earnings notes.
Want a deeper read on MTSR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Railpen lifts IP Group offer with cash, Nanopore stake and Metsera upside
proactiveinvestors.co.uk · Jul 20
IP Group shares jump 9% as Metsera deal drives return to growth
proactiveinvestors.co.uk · Mar 17
Metsera Inc. (NASDAQ:MTSR) Given Average Recommendation of “Hold” by Brokerages
defenseworld.net · Dec 8
Pfizer Completes Acquisition of Metsera
businesswire.com · Nov 13
Metsera shareholders vote for $10 billion acquisition by Pfizer
reuters.com · Nov 13
Why Metsera's Share Price Is Plummeting This Week
fool.com · Nov 12
Instacart Up on Earnings Beat; Metsera Down on Takeover Battle | Stock Movers
youtube.com · Nov 10
Pfizer to acquire Metsera after winning bidding contest against Novo Nordisk
proactiveinvestors.com · Nov 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.